ORGANIZATION STUDY

REPORT OF CIPLA

SUBMITTED BY,
DILNA VIJAYAN
MBA B BATCH
REG NO: 70859

1
 ACKNOWLEDGEMENT

First foremost, I thank the lord almighty for his perpetual showers of
blessing, which led to the successful completion of my summer
internship report. It gives me immense pleasure to present this report.

I express my heartiest gratitude to FISAT Business School, Angamaly for

permitting me to do this internship at Cipla Ltd, Goa.

I express my sincere gratitude to Miss. Biji U Nair, Faculty of FISAT

Business School for her valuable guidance for the successful completion
of the study.

I wish to express my heartfelt and sincere thanks to Mr.Viraj Snari the

Head of the Human Resources and all officials & employees of Cipla Ltd
for being very helpful and suggestive in giving the valuable informations
regarding their jobs and responsibilities in their respective concerns, for
the successful completion of the study.

I also thank my parents, friends and relatives for their help and
encouragement

And I also express thanks to MG University which enable us to gain a

practical experience working.

I perceive as this opportunity as milestone in my career department I will

strive to use gained skills and knowledge in the best possible way.

Dilna Vijayan

2
DECLARATION

I, Dilna vijayan.K.V hereby declare that the Summer Internship Report

entitled Organisation study Report of Cipla LTD has been written by
me after a thorough study during the month of April and May under the
supervision of Ajeesh Sebastian, head of the Human Resources, Cipla
Ltd, Goa and Miss Biji U Nair, Faculty guide, FISAT Business School,
and that no part of this report has formed the basis for award of any
degree, diploma, associate ship, fellowship or any other similar title or
recognition in any other institution.

Place: Mookkannor

Date: Dilna Vijayan

3
TABLEOF CONTENTS

INTRODUCTION............................................................................
Background of the study..................................................................................

Objectives of the study.....................................................................................

Scope of the study..............................................................................................

Method of Study.................................................................................................

Methodology.....................................................................................................

Limitation of the study......................................................................................

INDUSTRY PROFILE........................................................................
Industry profile....................................................................................................

Company Profile....................................................................................................

Major therapies of cipla.........................................................................................

Awards and achievements...................................................................................

ORGANIZATION CHART.................................................................
Organizational structure......................................................................................
Preparation of Ciplas pharmaceutical products...................................................

FUNCTIONAL DEPARTMENTS IN CIPLA.........................................

Human Resources department..............................................................................

4
Finance department.............................................................................................
Marketing department........................................................................................
Research and development..............................................................................
Operation department...........................................................................................
Quality control department....................................................................................
Quality Assurance department............................................................................

SWOT ANALYSIS............................................................................
Strength...............................................................................................................
Weekness..........................................................................................................
Opportunities........................................................................................................
Threat....................................................................................................................

FINDINGS AND CONCLUSION..........................................................

Findings.................................................................................................................
Conclusion..............................................................................................................

BIBLIOGRAPHY..................................................................................

5
CHAPTER 1
INTRODUCTION

6
1. BACK GROUND OF THE STUDY
Organization is set of people working together for accomplishment of a common
objective. The main purpose of the organisation is to attain certain and
predetermined goals. The roles and responsibilities are stated clear without any
ambiguity. The positions occupied by different individuals are presented in the form
of organizational structure, organization helps management to perform its activity
effectively, optimum use of technological improvement growth and diversification,
creatively, effective use of physical resources.

The summer internship programme is undertaken during 2 months. The main

purpose of the training is to know how an organization works and to gain experience
and expose ourselves to corporate policies, ethics, culture, practices, procedures,
facts about the work culture and policies of the company.

1.2 OBJECTIVES OF THE STUDY

To understand the organization structure or hierarchy of the company

To understand working of the various departments.
To know the functions and responsibilities of each department.

1.3 SCOPE OF THE STUDY

This report is based on the study conducted at Cipla Limited, Verna, Goa.

Its main aim is to understand the companys establishment, organisation

structure, various departments and its responsibilities, techniques, market
strategies and many more
Its aims to understand the skills of the company in the areas like technological
advancement, competition and in management.
It helps to analyze the companys performance in comparison to theoretical
aspects.

7
1.4 RESEARCH METHODOLOGY
The study has been accomplished through

Observing various departments in the organisation like finance, marketing, HR

department etc,
Face to face interviews with the company executives, managers employees
Surfing various websites, company annual report etc.

1.41 SOURCE OF DATA

PRIMARY DATA

It is collected through observation, face to face interaction and interviews with the
company, executives and employees of the organisation,

SECONDARY DATA

It is gathered from the organization catalogues, journals and books, company

websites, company manuals, company report etc.

1.42 TOOLS FOR ANALYSIS

SWOT Analysis has been used to analysis the companies strength, weakness,
Opportunities, and Treat.

1.5 LIMITATION OF THE STUDY

Time is an important constrains, since the study is only for 2

months.
The company managers were busy in their work schedule, it was
not possible to spend more time for discussion
As per the rules and policies of the company, executives were not
ready to disclose many in formations.

8
 CHAPTER 2
INDUSTRY PROFILE AND COMPANY PROFILE

9
INDUSTRY PROFILE
The pharmaceutical industry is the part of the healthcare sector that deals with
medications. The industry comprises different subfields pertaining to the
development, production, and marketing of medications. The pharmaceutical
industry, as a vital segment of the health care system conducts research,
manufacturing and marketing of pharmaceuticals and biological products and
medicinal devices used for the diagnosis and treatment of diseases.

The first pharmaceutical industry in India was Bengal chemical; it was started in
1930 by Prafulla Chandra Roy. The main goal of the pharmaceutical industry is to
provide drugs that prevent infections, maintain health, and cure diseases. This
industry directly affects the global population, so a number of international regulatory
bodies monitor things like drug safety, patents, quality, and pricing.

The pharmaceutical industry has made a great deal of progress over the last decade
due to a research-oriented approach that has improved technologies, developed
infrastructures, and increased research in the field of bioscience. Thanks to
biotechnology, various formulations have been developed to cure or stop the growth
of several major infections, including HIV and certain types of cancer.

The worlds pharmaceutical industry is dominated by the American and European

markets. Indeed, according to data from the World Health Organization.

10
GLOBAL SCENARIO
The global pharmaceuticals market is worth US$300 billion a year, a figure expected
to rise to US$400 billion within three years. The 10 largest drugs companies control
over one-third of this market, several with sales of more than US$10 billion a year
and profit margins of about 30%. Six are based in the United States and four in
Europe. It is predicted that North and South America, Europe and Japan will continue
to account for a full 85% of the global pharmaceuticals market well into the 21st
century. Companies currently spend one-third of all sales revenue on marketing their
products - roughly twice what they spend on research and development. The main
global pharmaceutical companies are:

Novartis

Pfizer

Amgen

Novo Nordisk

Sanofi

Some large pharmaceutical companies support health development through

public-private partnerships. In a number of cases, international corporations and
foundations have contributed drugs or products free of charge to help in disease
eradication. SmithKline Beecham has made a US$500 million commitment to
WHO of its drug albendazole, used to treat lymphatic filariasis (elephantiasis).
American Home Products has provided a non-toxic larvicide and the DuPont
Company has contributed free cloth water filters for the eradication of guinea-
worm disease (dracunculiasis). The Japanese Nippon Foundation has enabled
WHO to supply blister packs containing the drugs needed for multi-drug therapy
(MDT) of TB in sufficient quantities to treat about 800 000 patients a year in some
35 countries. The patients receive the treatments free of charge.

The global prescription drug market is expected to fare better in 2016 than the
previous year with a pick-up in growth. Yet the increase will not be as nearly as
dramatic as the one seen in healthcare expenditures across the world. Pharma
companies must cope with governments tightening of cost controls and growing
criticism of innovative drugs skyrocketing prices, especially in the United States.

The rise in cheaper generic drugs sales does help ease the financial burden on
public social security schemes. But as long as drug makers know they can cash in
on bringing novel drugs to market, the current bullish mood is likely to last.

11
The political debate on drug prices will range on in 2016, particularly in the United
States which is in the throes of a presidential election campaign. The topic might
even become a hurdle for drug makers. Still, this year could be marked by significant
clinical advancements in immuno-oncology.

INDIAN SCENARIO
The government started to encourage the growth of drug manufacturing by Indian
companies in the early 1960s.. The 20% of global exports in generics, making it the
largest provider of generic medicines globally.. Branded generics dominate the
pharmaceuticals market, constituting nearly 70 to 80 per cent of the market. India is
the largest provider of generic drugs globally with the Indian generics accounting for
20 per cent of global exports in terms of volume. Of late, consolidation has become
an important characteristic of the Indian pharmaceutical market as the industry is
highly fragmented.

India enjoys an important position in the global pharmaceuticals sector. The country
also has a large pool of scientists and engineers who have the potential to steer the
industry ahead to an even higher level. Total exports of Drugs, Pharmaceuticals for
2013-14 at USD 15,095 million, recording a growth rate 2.5% over the corresponding
period of previous years.

The Indian pharmaceutical industry is estimated to grow at 20 per cent Compound

Annual Growth Rate (CAGR) at over the next five years. The Indian pharmacy
industry, which is expected to grow over 15 per cent per annum between 2015 and
2020, will outperform the global pharmacy industry, which is set to grow at an annual
rate of 5 per cent between the same period!. Presently the market size of the
pharmaceutical industry in India stands at US$ 20 billion. As on March 2014, Indian
pharmaceutical manufacturing facilities registered with the US Food and Drug
Administration (FDA) stood at 523, highest for any country outside the US.

The government started to encourage the growth of drug manufacturing by Indian

companies in the early 1960s, and with the Patents Act in 1970However, economic
liberalization in 90s by the former Prime Minister P.V. Narasimha Rao and the
then Finance Minister, Dr. Manmohan Singh enabled the industry to become what it
is today. This patent act removed composition patents from food and drugs, and
though it kept process patents, these were shortened to a period of five to seven
years.

The lack of patent protection made the Indian market undesirable to the multinational
companies that had dominated the market. Whilst the multinationals streamed out,

12
Indian companies carved a niche in both the Indian and world markets with their
expertise in reverse-engineering new processes for manufacturing drugs at low
costs. Although some of the larger companies have taken baby steps towards drug
innovation, the industry as a whole has been following this business model until the
present.

The number of purely Indian pharma companies is fairly low. Indian pharma industry
is mainly operated as well as controlled by dominant foreign companies having
subsidiaries in India due to availability of cheap labor in India at lowest cost. In 2002,
over 20,000 registered drug manufacturers in India sold $9 billion worth of
formulations and bulk drugs. 85% of these formulations were sold in India while over
60% of the bulk drugs were exported, mostly to the United States and Russia. Most
of the players in the market are small-to-medium enterprises; 250 of the largest
companies control 70% of the Indian market. Thanks to the 1970 Patent Act,
multinationals represent only 35% of the market, down from 70% thirty years ago

Most pharma companies operating in India, even the multinationals, employ Indians
almost exclusively from the lowest ranks to high level management. Homegrown
pharmaceuticals, like many other businesses in India, are often a mix of public and
private enterprise.

In terms of the global market, India currently holds a modest 12% share, but it has
been growing at approximately 10% per year. India gained its foothold on the global
scene with its innovatively engineered generic drugs and active pharmaceutical
ingredients (API), and it is now seeking to become a major player in outsourced
clinical research as well as contract manufacturing and research.

13
COMPANY PROFILE CIPLA LIMITED

Cipla was born out of Dr. K.A. Hamieds vision to harness Indian expertise for self-
sufficiency in the chemical and pharmaceutical industry in India. Dr. K.A. Hamied
was an exemplary visionary who donned various hats; he was a chemist, an
entrepreneur and pioneer, an active participant in Indias independence struggle, a
close ally of Mahatma Gandhi, Dr. Zakir Hussain and various others, a legislator in
the Bombay Presidency, head of various associations, Sheriff of Bombay, proactive
supporter and sponsor of institutes of scientific excellence in India.

Goal of the company is to ensure that no patient shall be denied access to high
quality and affordable medicine and support

The mission of the company is to be a leading global health care company which
uses technology and innovation to meet everyday needs of all patients.

Be it the commencement of bulk drug production in India, the landmark Indian

Patents Act of 1970, the several firsts in India and the world, its historic international
stance on the price and availability of antiretroviral drugs for HIV treatment in 2000-
2001, its free-of-cost Palliative Care Centre for terminally-ill cancer patients, Cipla,

14
under the leadership of its current Chairman Dr. Y.K. Hamied, has stood for
fearlessness and compassion. It is not for nothing that we say None Shall be
Denied.

Apart from its various national and international milestones, the story of Ciplas
growth and expansion, its ups and downs, successes and challenges is also one that
deserves to be chronicled. According to Dr Y K Hamied, Cipla was ranked 56 in the
1960s.

It is with this view that the Cipla Archives project has been launched recently. They
treat their proud legacy with the seriousness and the sense of responsibility it
deserves. They want to share Ciplas story, celebrate its rich history, remind
ourselves of the lessons learned, and reflect on the evolution of the pharmaceutical
industry in India and at Ciplas role in shaping it.

Ciplas history contribute to the development of business archives in India, and serve
as a forum for debates and discussions on the history and historiography of science
and the pharmaceutical industry in India.

For patients, caring is a promise that the company will do whatever it takes to ensure
they have continued access to the highest quality medicines at affordable prices;
whether a disease affects millions or just a few hundreds.

To the medical fraternity, caring means the assurance of world class medicines and
support across multiple therapeutic areas. For the business partners, caring bring
the confidence of always getting world class quality and competitive prices.

For the employees, caring manifests itself in a safe, equal opportunities work place
that faster innovation for a healthier world.

Cipla is an Indian multinational Pharmaceutical and biotechnology company, head

quarter in Mumbai, India, Belgium and surrey in the European Union and Florida,
Indore etc.. Cipla Primarily develops medicines to the widget range of dry power
inhaler devices, nasal sprays- A variety of nasal sprays for treatment of nasal allergy,
multi haler- Multi dose dry powder inhaler, Baby mask and infant mask- For delivery
of inhaled medications to young children, zerostat VT-Non static spacers.

Cipla has emerged as one of the worldss most represented pharmaceutical names
not just in India but worldwide. They maintain world class quarterly across all out
products and services. Cipla has 34 manufacturing facilities across India. Company
has dedicated plants for the technologically challenging formulations such as
oncology products Hormones, Metere dose inhalers, Beta Lactams, Cutotoxic,
injectectable and cephalosporins .Their manufacturing plants and processes are

15
 seen as among the most sophisticated in the world. They roll out world class
products in over 65 therapeutic categories. They use state of the art technology, the
most stringent operating procedures, a highly motivated and technologically
competent team, highest standard of safety practices and environmentally green
and clean processes.

Cipla has been at the forefront of innovation for inhalation therapy in India. The
Company has played a leading role in educating the nation on inhalation therapy and
over the coming years we will continue to work on topics such as patient awareness,
acceptance, compliance and usage, physician training, medical camps and
counselling. Strongly focused on access and affordability, Cipla Respiratory
continued to strengthen its efforts through the BreatheFree patient awareness and
education programs across markets, dedicated to making a difference to both
patients and medical practitioners.

Over the last 40 years, the Company has been focused on bringing this innovation to
markets across the globe. The revenue of the Cipla is 104.83 billion.

TABLETS & CAPSULES AEROSOLS pMDI RESPULES INJECTIONS

23 Billion UNITS 75 Million 400 Million units 5 Million units 45 Million units

CIPLA

CAPACITY

APIs SEAL EYE DROPS UNIMS ORAL LIQUIDS

16
 60 Million units 60 Million units 35 Million units 800 ns

A pioneer in Active Pharmaceutical Ingredients (API) manufacturing in India

for over 5 decades, Cipla currently manufactures more than 200 generic and
complex APIs. Cipla APIs cover a broad spectrum of therapeutic categories that are
supplied to some of the major formulation players in the pharmaceutical industry
globally - over 350 Drug Master Files (DMF) and 70 Certificate of suitability of
Monographs of the European Pharmacopoeia (CEPs).
In addition, Cipla has a robust pipeline of over 50 APIs at various stages of
development.
Cipla maintains long-standing relationships with its existing partners on
several APIs to support them in establishing leading positions for their markets.
Cipla takes pride in its network of modern API manufacturing facilities, all
approved by the US FDA and other major international regulatory agencies. The
company also maintains the most stringent international standards of quality for all
its products.

CIPLA GLOBAL ACCESS

Since its inception, Ciplas ethos has been firmly rooted in the vision None shall
be denied. The Company strongly believes that access to high quality, affordable
medicines is a basic human right.

Cipla Global Access (C-GA) is a tender based institutional business that

concentrates on four key therapy areas: HIV/AIDS, malaria, multi drug-resistant
tuberculosis, and reproductive health.

Cipla has by far the highest number of ARV products approved for the treatment of
both children and adults. In addition newer molecules in novel dosage forms (e.g.
pellets) are being developed to help optimize dosage for the current regimens, for
the treatment of children and also reduce the pill load, thereby offering better
adherence and success of treatment. Cipla is adding new capacity for the growing
demand for ARV products and expect the expansion to be completed in 2016-17.
Cipla is also one of the largest suppliers of antimalarial drugs in the world. This
portfolio covered treatment for over 55 million malaria patients across all the affected
countries. The coverage is increasing every year and thus saving millions of lives.
Cipla anti-malarial treatment costs less than a dollar for the entire course. Cipla has
always been at the forefront in initiatives to identify, develop, manufacture & supply
low cost treatment with the artemisinin-based combination therapy (ACTs). All the
ACTs supplied by Cipla are approved by WHO. Cipla is endeavoring to expand its

17
portfolio. It will be expanded with more potent and safer antimalarials, using novel
drug delivery systems.

Cipla has a strong second line (SLTB) portfolio for treating multidrug resistant TB
(MDR TB). It is aggressively expanding its MDR TB portfolio to meet the challenges
of resistance which develops among TB patients due to the high rate of dropout from
treatment. Till now, Ciplas SLTB drugs catered to a moderate patient base globally,
but this is likely to increase significantly with the use of new diagnostic methods of
detecting drug resistant TB. Future development in the MDR TB therapy area will be
focused on newer molecules which can significantly reduce treatment timelines.
Currently, Cipla services around 70 countries in this area.

Reproductive health and family planning segment is an emerging segment in which

Cipla currently caters to over 300,000 patients worldwide. Cipla has aligned its
strategy with international development initiatives to provide safe and effective
contraceptive drugs for 120 million more women by 2020.

Cipla Global Access also provides medications for infections caused by helminths,
schistosomiasis and kala azar, which pose major health threats in low and middle
income countries (LMIC).

The commitment to high quality standards has made Cipla the most trusted brand
among healthcare professionals. Cipla today has 12 divisions reaching out to more
than 20 specialties from general-practioners to super-specialists. Cipla is a market
leader in three therapies Respiratory, Urology and Antiretroviral (ARV) with seven
brands in the top 100 list.

In the fiercely competitive Indian pharmaceutical industry environment, Cipla scores

over with strong brand equity, product range, unique dosage forms, pioneering work
across therapeutic areas, numerous medico-marketing initiatives, strong distribution
network of distribution depots catering to a network of over 3,000 stockists, reaching
out to 7,00,000 chemists and more than 10,000 colleagues with can-do attitude.

Ciplas approach is to understand unique patient requirements and develop

solutions, and also focus on enhancing patient awareness and medical education.

Cipla Medpro, a 100% subsidiary of Cipla Limited, has a strong presence across
therapies in the Republic of South Africa. Cipla also won government tenders in
antiretrovirals (ARV), respiratory and newer areas such as mental health,
cardiovascular and womens health categories.

18
Ciplas manufacturing facility at Durban provides a competitive edge and is the first
Pharmaceutical Inspection Convention (PIC) compliant facility in the country. The
brand inspires trust and has become a household name amongst consumers,
pharmacies, prescribers and key opinion leaders.

Cipla has a clear commitment to provide access to Africa and other LDCs (Least
Developed Countries). Cipla Quality Chemical Industries Limited ( CiplaQCIL ) is a
state of the art manufacturing plant in Uganda that manufactures WHO prequalified
anti-retrovirals antimalarials and antivirals for the treatment of hepatitis B. The plant
is the largest in East Africa and supplies the Ugandan market and exports to East
Africa, Cameroon and various markets in southern Africa. CiplaQCIL is currently
expanding its portfolio to manufacture medicines for tropical diseases such as
sleeping sickness, worm infestations and hepatitis C.

Cipla in South Africa as one of the largest pharmaceutical companies in South

Africa, Cipla has a market share of more than 5%. South Africa contributes 14% to
the overall Cipla revenues on a consolidated basis. The South Africa business
revenue has grown at 9% in the private market over the last three years. On a like
forlike basis, the South Africa business registered a revenue growth of 4% for the
year. The Cipla brand inspires trust and has become a household name among
consumers, pharmacies, prescribers and key opinion leaders.

The private market contributed 73% of revenues. Cipla also won Government
tenders in antiretrovirals (ARV), respiratory and newer areas such as mental health,
cardiovascular and women's health categories. The manufacturing facility at Durban
provides the Company a competitive edge and is the first Pharmaceutical Inspection
Convention (PlC)compliant facility in the country. The manufacturing unit generated
a profit, as compared to a loss last year, achieved by significantly improving
utilization, improved efficiencies and cost control measures.

Capitalizing on its defined future portfolio, key development and inlicensing

projects, and streamlined global organizational structure, Cipla South Africa will
leverage synergies from its international family. Plans are on track and the
integration across manufacturing supply chain, finance and human resources is
complete. The Company has leveraged its skill and scale to drive down costs in
areas such as procurement.

Aligning with Cipla's philosophy of providing South Africans with access to a broader
range of affordable medicines and leveraging the leadership position in South Africa,
Medpro Pharmaceutica (Pty) Ltd a subsidiary company of Cipla Medpro
entered into a sales and distribution arrangement with Teva Pharmaceuticals (Pty)
Ltd, an affiliate of Teva Pharmaceutical lndustries Ltd. The collaboration will focus on
the following therapeutic areas: oncology, central nervous system, women's health,
cardiovascular, ophthalmology and other specialty products.

19
Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several
countries in Europe through its partners and own network. Cipla is focused on
offering a new pharma concept built on layers of value such as newer products,
concepts, formats, information and services to help healthcare providers across
Europe. Cipla is making innovative, affordable medication accessible in over 20
countries across Europe. The European business contributed 4% to the overall
Company revenues, recording a decline of 24% in revenues for the year. The drop
was driven by a oneoff event in the previous year, a decline in partner based
business and some supplyrelated issues. Plans have been put in place to address
these issues and regain business momentum.

Cipla is focused on adding innovative elements to products, services and information

through research and partnerships. We now have seven different inhaler products in
the market in at least one European country. Our flagship product, the salmeterol
fluticasone MDl, is now in the market in Croatia, Germany, Czech Republic,
Slovakia, Belgium and Hungary. The pricing level is set in accordance with the rules
set out by individual countries, our estimation of affordability per country and our cost
of goods, so the price differs somewhat from country to country.

Cipla Europe NV signed a distribution agreement with Serum lnstitute of lndia Ltd.
(Sll) to market pediatric vaccines in Europe and expects to commence filings in the
near future.

Cipla also signed an exclusive partnership with BioQuiddity to market OneDose

ReadyfusORTM in anesthetic applications for postsurgical pain management. Cipla
intends to launch the CE Marked One Dose Readyfus ORTM prefilled with
ropivacaine under its own label in Europe in the next year. The readytouse
infusion systems are nonelectric, ambulatory, and should enable seamless
transition between sites of care.

Cipla offers range of products in Europe Respiratory, HIV, Vaccines, OTC, API,
Plain Generics and Hospital products. Cipla is focused on adding innovative
elements, products and services by building direct-to-market presence in several
countries.

Cipla USA., Inc., the US subsidiary of Cipla Limited, is the first Indian company to
be approved by US FDA in 1985. Through a comprehensive partnership approach
model, Cipla has been dedicated to providing access to medicines to US patients for
over 30 years.

The company has executed US partnerships and has commercialized products in

the US. Cipla has supported the development of more than 170 ANDAs.

20
Cipla has an active internal pipeline including several key respiratory products and
other complex generics. Cipla launched its US label in January 2015. In September
2015, Cipla's UK arm, Cipla EU has entered into definitive agreements to acquire
two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan
Pharmaceuticals Inc

Cipla has a wide presence internationally, covering South-East Asia, Middle-East,

Latin America, Africa, Australia, New Zealand and Russia-CIS. The company offers a
diverse range of more than 1000 products in over 100 countries.

Cipla has further strengthened its position by establishing its own company and
brand presence in 17 markets including Algeria, Morocco, Malaysia, Vietnam, Yemen
and Sri-Lanka among others, adopting the direct-to-market (DTM) approach.

With a footprint across five continents, Cipla is moving fast towards its goal of
making affordable healthcare available to all.

The Company's revenue from operations on a consolidated basis during the financial
year 201415 amounted to Rs.11,345 crore against Rs.10,173 crore in the previous
year, recording a growth of 11.5%. The income from operations for domestic
business increased by 18%, from Rs.4,090 crore in the previous financial year to
Rs.4,825 crore in the financial year under review. Total exports increased by 5.6%
during the year to Rs.6,058 crore. During the year under review, operating margin
reduced by 2.7%. This was primarily due to the change in product mix, higher
investments in research and development, and talent acquisition. Profit for the year
reduced by 15% to n,181 crore from Rs.1,389 crore in the previous financial year.

India Ratings and Research Private Limited, a Fitch Group Company, assigned a
LongTerm Issuer Rating of IND AAA with a stable outlook to the Company. The
rating is the highest assigned in Fitch's rating scale and indicates the highest degree
of safety regarding timely servicing of financial obligations and lowest credit risk.

No material changes and commitments have occurred after the close of the year till
the date of this Report, which affect the financial position of the Company.

CIPLA IN INDIA

21
As one of India's leading pharmaceutical companies, Cipla is in a strong position to
fulfill its commitment to provide modern and affordable medicines to patients. This
year, despite the challenges, as per IMS Health data, Cipla's domestic business
revenues grew by 20% compared to the industry growth of 12%.

India business contributed 42% to overall Company revenues, with new products
contributing 3.2%. Market share of our branded generics currently stands at 5.27%.

Cipla continues to focus on inlicensing opportunities. In FY 201415, Cipla has in

licensed darbepoetin. Cipla successfully launched the generic drug sofosbuvir in
India for the treatment of hepatitisC under the brand name HepCvir. In India alone it
is estimated that 1218 million patients are infected with hepatitisC, of which up to
2 million may need treatment. Sofosbuvir is a new antiviral drug which in
combination therapy has shown to have higher cure rates. It represents a
breakthrough in the treatment of hepatitis C.

In the coming years, the domestic business will continue to focus on these themes:

Grow well ahead of market growth

Execute plans for the priority business segments

Strengthen our leadership in therapy and geography

Focus on building current and future product pipeline

Increase sales force productivity with the rollout of Customer Relationship

Management (CRM) and Sales Force Automation (SFA) systems

MAJOR THERAPIES OF CIPLA

CARDIOVASCULAR

Forty years ago, Cipla started its fight against heart disease with innovative and
high-class drugs. They introduced Propranolol, the first beta blocker in India way
back in 1972. This ushered in a new age of affordable beta blockers. Over the years,
they have developed several products that help treat various diseases like MI,
angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, and
obesity. Apart from innovation in cardiology, they also provide valuable services to
the medical fraternity, in the form of the latest medical updates, CMEs and
workshops. Not to mention many international symposia and webcasts with the
worlds leading minds in cardiology, and conferences conducted in collaboration with
international scientific bodies.

22
 Besides, they are committed towards disease detection and patient awareness
programmes like KBC (Know your Blood Cholesterol) and Check BP which can help
doctors reach hundreds of undiagnosed patients and improve patient care and treatment
adherence.

In the years to come, we shall continue to introduce novel drugs and combinations.
They are also exploring the therapeutic potential of stem cells as part of our
commitment to fight heart disease.

DIABETES

Cipla has played a significant role in diabetes treatment and control and has
developed a range of anti-diabetic drugs for the management and control of diabetes
and the treatment of complications that arise due to it. Besides, the doctor and
patient services are aimed at creating greater awareness to fight the disease.

Some of ciplas highlights:

They have several products as single and combination pills to treat diabetes:
Metformin, a single drug, Metformin plus Glimepiride, a dual combination and
Metformin plus Glimepiride plus Pioglitazone, a triple drug combination.
They also have drugs to manage diabetic complications like Atorvastatin and
Fenofibrate for high cholesterol, Pregabalin for painful diabetic neuropathy and
Cilostazol for intermittent claudication.
Physical activity is one of the key factors in controlling glucose levels. We have
made considerable efforts to educate patients about the importance of exercise in
diabetes management. One of their unique tools is an exercise reminder on the flap
of each pack.
They conduct several clinics where we regularly carry out the screening of
patients for early diagnosis of diabetes and its complications.
They provide valuable services to the medical fraternity - the latest medical
updates, CMEs, workshops and conferences conducted in collaboration with
international scientific organizations.
In fight against diabetes they are committed to introduce new drugs and patient
services that focus on better management of this disease.

HIV/AIDS

Cipla has been committed to the cause of HIV/AIDS for over two decades. In
crusade against the disease, they have developed over 15 single and combination
medicines that revolutionized HIV therapy, not just in India but across the world.

23
 In 2001, they introduced the worlds first ever recommended 3-in-1 fixed dose
combination (Stavudine + Lamivudine + Nevirapine) to fight AIDS. It was made
available at less than $1 per day compared to over $12,000 per patient per year
prevailing in most countries throughout the world. It lifted the death sentence from
millions across the developing world. They have also done pioneering work in
pediatric HIV and addressed the needs of every kind of HIV patient, from pregnant
mothers to babies and from children to adults.

Not surprising that today around 1 million patients in the world are on our
antiretrovirals, and with regular therapy they can live for years and lead a near
normal life. Besides, world class scientific resources and educational platforms are
helping physicians across India and the world manage the disease effectively. Cipla
have even given our support to the development and dissemination of guidelines for
the medical community in India.

MALARIYA

It has always been Ciplas mission to reach out whenever there is a need. Thats
why they are committed to fighting malaria, one of the worlds most dreaded
diseases. It is a leading cause of death due to limited availability of anti-malarial
drugs and accurate diagnosis.

The fight against malaria goes back to World War II when we made quinine available
to soldiers fighting in the eastern part of India. In the 1960s and 1970s, the incidence
of malaria in India came down dramatically due to Government initiatives which used
insecticides to kill the mosquito which carries the parasite that causes malaria.
However, the mosquito developed resistance to insecticides and the malaria parasite
to chloroquine. In order to counter this, we relaunched quinine, one of the most
potent and effective anti-malaria drugs. Since then, they have made a significant
contribution of anti-malarial products, not just to India, but to the world. We are one
of the largest suppliers of anti-malarial drugs in the world.

HEPATITIS

Cipla has played a significant role in the management of Hepatitis B & C with a wide
range of drugs. Our role in health care goes beyond providing the best drugs for
diseases to equipping doctors and their patients with the latest information available,
aimed at creating greater awareness to fight against the disease.

Some of the highlights:

Cipla have one of the widest range of products for hepatitis B and C in India.

24
 Cipla have drugs to treat Hepatitis B like tenofovir, entecavir, peg-interferon
alfa 2-b and lamivudine and for Hepatitis C like sofosbuvir, ledipasvir-sofosbuvir
fixed dose combination and daclatasvir.
In Ciplas fight against Hepatitis, we are committed to introduce new drugs
and patient services that focus on better management of these diseases.
Hepatitis B & C are often known as silent diseases as patients are usually
unaware of the infection. To increase awareness, our initiatives for Hepatitis B & C
are B-Involved and ACT-C respectively which are aimed at creating greater
awareness by educating patients on Hepatitis B & C.
They work closely with the medical fraternity and provide valuable services
including the latest medical updates, continued medical education (CMEs),
workshops and conferences
They conduct several camps/clinics where we assist in screening patients for
early diagnosis of hepatitis and its complications.
The journey doesnt end here. Ciplas endeavour is to support patients suffering from
Hepatitis B & C and will continue to work with healthcare providers to increase
disease awareness and ensure access to the latest treatments at affordable prices.

UROLOGY

Cipla has a significant presence in urology, with products in prostate ailments BPH
(Benign Prostatic Hyperplasia), prostate cancer, bladder disorders, urinary stones,
hypogonadism and sexual dysfunction ailments. Besides developing many of Indias
firsts in this therapy, we have to our credit the worlds first combination products
containing Tamsulosin + Finasteride and Tamsulosin + Dutasteride...milestones in
the history of urology.

Some of Ciplas other important products in urology include:

A selective alpha-blocker that reduces the chances of surgery for BPH
patients.
Bicalutamide for prostate cancer.
Potassium citrate and Magnesium citrate solution for the treatment and
management of urinary stones.
To maintain their leadership position, they work closely with urologists and surgeons
and support a range of initiatives for those working in the field of urology. They export
our urology products to several countries around the glob

AWARDS AND ACHIVEMENTS

In 1980 Cipla won Chemixcil award for excellence for exports.

In 2005 Forbes included Cipla in the 200 best under a billion list of best small
Asian Company.

25
 In 2006 won Dun & Broad street American Express corporate Award .

In 2012 Cipla received the Thomson Reuters India Inovation Award.

26
 CHAPTER 3
ORGANIZATION CHART

27
 ORGANIZATION CHART

BOARD OF
DIRECTORS

MANAGING
DIRECTORS

DEPUTY MANAGERS

R&D
QA
MANAGER FINANCE
MANAGER
HR MANAGE
MANAGE R
R PLANT
QC MANAGE
MANAGER R

MARKETING
MANAGER

PROGRAMMIN PRODUCTIO ENGINEERING

G MANAGER N MANAGER DEPARTMENT
MANAGER

28
PREPARATION OF THE PHARMACEUTICAL PRODUCTS IN CIPLA

Chemical Micro-Organic Vegetable

substances cultures or animal
tissues

Fermentation

Synthesis Pharmacologica
Extraction
lly active
substance

Drying Comminution

Dilution in Proportioning Mixing with

liquids solid
excipients

Syrup, Pastes
drops &

Ointments Powders
Freeze-
drying Suppositorie
s

Direct
use( antibiotics Capsules
Freeze- in powder form)
Granules
dried
products Tablets

Pills
External
cleaning(antibio
tics in powder
form)

packaging
FUNCTIONAL DEPARTMENTS IN CIPLA
29
There are 7 departments in Cipla ltd, Goa

1. HUMAN RESOURCES DEPARTMENT

2. FINANCE DEPARTMENT

3. MARKETING DEPARTMENT

4. RESEARCH AND DEVELOPMENT DEPARTMENT

5. OPERATION DEPARTMENT

6. QUALITY CONTROL DEPARTMENT

7. QUALITY ASSURANCE DEPARTMENT

1. HUMAN RESOURCES DEPARTMENT

Human Resource Management (usually referred to as HR) involves everything

related to the employer-employee relationship and is about supporting and managing
the organisations people and associated processes. Its seen as a core business
function essential to the organisations effective operations. The Human Resources
department can be overlooked at new or expanding businesses. In fact, an effective
HR team can be among a growing firms most important assets. It can help protect a
company from liability, maintain a satisfied workforce and bring the brightest talent to
a company. By its nature, the HR department will take on a variety of responsibilities
that can boost a companys ability to grow.Human Resources department takes care
of human resources of the organisation. Human Resources (HR) and Compliance
share a common goal of facilitating, monitoring, and enforcing employee compliance.
The human resources department can provide the organization with structure and
the ability to meet business needs through managing the company's most valuable
resources -- its employees. The Human Resources department can play a key role in
communicating an organizations goals and expectations to workers. HR staff may
produce a company newsletter or magazine, filled with events, opportunities, news
and useful information that helps employees accept and understand what the
organization needs from its workforce. In addition, HR staff members are able to
keep an ear to the ground, keeping tabs on the company rumor mill and helping
management respond to misconceptions among employees. The HR department
can take on the challenge of providing employees with the new information and skills
they will need to thrive as the company changes.

In cipla HR department has divided into 4 parts

30
 HR department

Time office Pay roll Recruitme Training &

nt Developm
ent

TIME OFFICE

Time Office Functions Maintenance of Employee - entry card / time card -

Muster roll / attendance register - contract worker muster roll - Feeding
working days for salary - coordination with all employees - timely welfare -
control of security dept.

Web smart system is the soft ware through which the time office set work in
Cipla. Time office maintains, monitored and updates the attendance. Time
office has a right to login to web smart by using location, user ID, and
password. Through this software time office can view the full options. The
options like master leave sanction, time sanction, data utilities, report etc.

PAY ROLL

Payroll is the sum total of all compensation a business must pay to its employees for
a set period of time or on a given date. It is usually managed by the accounting
department of a business; small-business payrolls may be handled directly by the
owner or an associate. Payroll can also refer to the list of employees of a business
and the amount of compensation due to each of them. Payroll can differ from one
pay period to another due to overtime, sick pay and other variables.

In cipla the payroll processing they uses the software named sambanth.In this they
uses the employee ID of the employees and print the attendance list of the
employees and they calculate the total number of days that the employees worked
and entered the working days in to the soft ware and finally process the payroll of the
employee. Then it gives to the HR head for the signature and finally send it to the
financial department.

31
RECRUITMENT

The recruitment process is the value added HR Process. It is about attracting,

interviewing and hiring new employees. The perfect recruitment includes the
adaption of the new hire. It is about the definition of the job vacancy, designing the
appealing recruitment text and offering the competitive package to the winning
candidate. The recruitment process is managed by the recruitment strategy. HR
should always find the right position on the job market as the candidates flow
smoothly through the organization.

The success of recruiters and employments specialists generally is measured by

number of position they fill and the time it takes to fill those positions. Recruiters are
plays a key role in developing the employers work force. They advertising job
posting, source candidates, screen applicants, conduct preliminary interviews and
coordinate hiring efforts with managers responsible for making final selection of
candidates.

In cipla having 10 manufacturing units of production. Each unit have assisted one
HR and he initiates the activities of each his unit. He analysis the unit and find out
the vacancies and inform the HR head. Them they give the advertisements and

32
collects the datas of the people and then they select the candidates an call them for
the interview. One HR should be attended that interview. Finally they select the more
suitable candidate. In Cipla they also conduct recruitment through campus selection.

TRAINING AND DEVELOPMNT

Training and development is vital part of the human resource development. It is

assuming ever important role in wake of the advancement of technology which has
resulted in ever increasing competition, rise in customers expectation of quality and
service and a subsequent need to lower costs.

In Cipla they gives the full day training and development programme for all the new
employees. In that they trained the workers according to the goals of the company.
They introduce the rules and regulations of the company in to the employees.

2. FINANCE DEPARTMENT
The part of an organization that manages its money. The business functions of a
finance department typically include planning, organizing, auditing, accounting for
and controlling its company's finances. The finance department also usually
produces the company's financial statements.

The finance department is also responsible for management of the organizations

cash flow and ensuring there are enough funds available to meet the day to day
payments. This area also encompasses the credit and collections policies for the
companys customers, to ensure the organization is paid on time, and that there is a
payment policy for the companys suppliers. In most organizations there will be
some form of forecast prepared on a regular basis to systematically calculate the
ongoing cash needs.

Where there are cash needs beyond the day to day working capital, the finance
department is responsible for advising and sourcing longer term financing.
Financing may be obtained though bank or private lender debt or, in applicable firms,
share issues to private investors. If the organization is ready to target angel
investors or venture capitalists the finance department will be key in preparing the
documents required for these presentations and may work with outside consultants
on a company valuation. In larger firms considering public share offerings the
finance department will assist with the preparation of the offering documents but will
likely also use outside consultants to advise on this complicated process.

Finance Departments, which play a vitally important role in the growth of all
establishments as well as the achievement of business goals, is generally consists of

33
the divisions of Collection and Client Credit, Payments, Accounting, Production
Costs, Financial Process Development, Reporting and Budgeting.

Board of directors

President

Finance Manager

Treasury Function

Credit Cash Banking Portfolio

Manageme managem Relation manageme
nt ent nt

Control Functions

Cost Tax Internal Budgeting

Control Control Audit

Cipla the financial managers perform data analysis and advise senior managers on
profit-maximizing ideas. Financial managers are responsible for the financial health
of an organization. They produce financial reports, direct investment activities, and

34
develop strategies and plans for the long-term financial goals of their organization.
In Cipla the finance department having mainly 2 functions, Treasury functions and
control functions.

The treasury department in Cipla is to manage the liquidity of a business. This

means that all current and projected cash inflows and outflows must be monitored to
ensure that there is sufficient cash to fund company operations, as well as to ensure
that excess cash is properly invested. While accomplishing this mission, the
treasurer must engage in considerable prudence to ensure that existing assets are
safeguarded through the use of safe forms of investment and hedging activities.

In this the manager in the treasury is passed the salary of the workers and all other
payments. The treasury department manager is to maintain and coordinating the
banking relations with the company.

Control function is the critical examination of the organization. They are responsible
for the cost, tax and budgeting control of the company. They conduct the auditing in
the company for to check on the process or transactions done for the business of the
company. The finance manager is responsible for conducting auditing in the Cipla.
After that they prepared the records of the works done in various departments in the
company and finally they sent that reports to the management. Through this the
management can be analyse the works that going on various departments in the
company.

According to the reports of the departments the management take actions and adopt
various methods for the improvement of the departments. For taking any actions or
adopt any new methods before that in Cipla the management conduct a conference
with all the department heads and ask their own opinions. Finally they adopted the
various new methods or policies.

35
3. MARKETING DEPARTMENT

The marketing department has overall responsibility for growing revenue, increasing
market share and contributing to company growth and profitability. In a small
business, the marketing department may just be one person, or it may include a
marketing director or manager plus marketing executives responsible for functions
such as advertising, publications or events.

The goal of marketing departments is to promote new products and treatments, to

present updated information in these areas to the Turkish medical world and to raise
public awareness regarding health issues.

Market research is a key responsibility for the marketing department. Research helps
the company identify market opportunities and gain a better understanding of
customer needs. It also helps them understand competitors strengths and
weaknesses so they can take action to protect business with existing customers or
win business from weaker competitors. The department can carry out its own
research by studying industry reports, market data on websites, or by contacting
customers and prospects to survey their needs and attitudes. Alternatively, they can
brief a market research firm to carry out the research.

The marketing department works with Internal or external product development

teams to develop new products or improve existing ones. The department analyzes
sales of existing products and identifies gaps in the product range where there may
be opportunities for the company. Marketing employees provide development teams
with information on customer needs and preferences to help them identify the
features or improvements to incorporate in new products.

Marketing departments plan campaigns and develop communications material to

promote products and services to customers and prospects. Depending on their
available budgets, they may plan advertising campaigns, develop e-mail marketing
programs, create promotional content for the company website, write press releases
or product publications, such as product leaflets, company brochures, product data
sheets or customer newsletters. They may write and design the promotional material
if they have skills within the department or they may appoint advertising agencies or
design firms to produce the work.

Cooperation between the sales and marketing departments can improve sales
performance and speed up business growth. The marketing department can provide
sales teams with high-quality leads by running advertisements that include a reply
mechanism, such as a coupon or telephone number, or by encouraging visitors to
the company website to register their details in return for a free newsletter or special
report. Marketing also prepares presentations for the sales team and supplies them
with stocks of promotional material to give to customers and prospects.

36
 Advertisin sales Productio
g n

Pricing

Packaging

Market
department

Research &
Developme Distributio
nt n

Market Public Event

research relations manageme
nt

In cipla the marketing manager responsible for the all the activities related to the
marketing of the products. They also conducted event management for the
promotion and advertising of their products. They also conducted various surveys for
analyzing the customers opinions regarding the products; on the basis of the survey
they adopted various new development and measures in their products. Through this
they can be maintain the public relations.

37
 4. RESEARCH AND DEVELOPMENT

Cipla pioneers among Indian pharmaceutical companies to see tremendous value in

investing in research & development (R&D). Our early investments in R&D,
beginning three decades ago, enabled us to make technology our key differentiator
and develop a basket of robust products for diverse markets across the world.
Ciplas core strength lies in our ability to excel in developing generics and
technologically complex products through focused teams in formulations, process
chemistry and analytical development. The company have the capability to deliver
quality products within established timelines, at low costs and without compromising
on quality.

Cipla's Research & Development is focused towards developing new products,

improving existing products as well as drug delivery systems and expanding product
applications. Hundreds of scientists work on all facets of pharmaceutical
development and technology.

In-house R&D forms the backbone of their operations. With almost 5-6% of the
company turnover being invested towards R&D each year, the strategy focuses on:

Developing new drug formulations for existing and newer drug substances
Improving processes for existing API and formulation products
Developing new drug delivery systems for existing and newer active drug
substances, as well as newer medical devices, mainly in the area of respiratory
medicine
Tie-ups with independent research teams to develop new products
Strengthening our intellectual property, including the patenting of new
products, drug delivery systems and medical devices, mainly in the area of
respiratory medicine
Conducting clinical and bio-equivalence studies for obtaining regulatory
approvals for new products and services
In addition, for our international business, our R&D team works with our strategic
partners to file Drug Master Files (DMFs) and Abbreviated New Drug Applications
(ANDAs) in the US, and seek marketing authorizations in Europe and file product
registrations in other jurisdictions.

38
 Cipla have earned a name for maintaining world-class quality across all our
manufacturing units, products and services. We have consistently introduced more
than 40 products annually, over the last decade.

Cipla have been granted about 100 patents. Patent filing includes drug substances,
drug products, platform technologies, IP on polymorphs and crystallinity, and medical
devices.

They also leverage our R&D efforts to provide our customers with technical dossiers,
plant layouts for pharmaceutical product manufacturing, development of processes
and regulatory batches.

Cipla has over 2000 products in 65 therapeutic categories available in

over 40 dosage forms, including:
Liposome Injection
Microsphere Injection
Topical Delivery System
Inhalation Technology:
o Metered-Dose Inhaler
o Dry Powder Inhaler & Respiratory Solutions
Nasal Drug Delivery
Ophthalmic Solutions
Pre-filled Syringe
Hormone Injection
Nanotechnology
Melt Extrusion & Hot Melt Granulation
Particle Engineering

FORMULATION DEVELOPMENT

Formulation pipeline has 250+ complex products where >75% is development

for International markets majorly in Respiratory, Oncology, ARVs, Ophthalmology,
CNS, CVS etc.
Ciplas development lab is equipped with state-of-the-art infrastructure for
development of innovative technology products.
Cipla develops and applies skills to ensure the quality of its products right
from the design to the manufacturing stage safeguarding patients safety and
efficacy of the products.
The development process for the products followed, ensures formulation
development based on Quality by Design (QBD) principles enabling robust,
reproducible and regulatory complied products in the market.

39
 Active pharmaceutical Ingredients ( API)DEVELOPMENT

Ciplas mission of providing affordable medicines across many therapeutic areas

globally is duly supported by the relentless efforts of a team of more than 300
dedicated and talented scientists.

Cipla houses state-of-the-art research facilities for its API process development at
three locations in India, with dedicated teams working on synthetic, organic
chemistry, process engineering and analytical development at multiple locations.

API pipeline consists of 75+ complex developments in the therapy areas of

Oncology, Hep C, ARV, Diabetology, CVS, CNS, Respiratory etc.
Cipla uses latest technologies like process analytical technology, continuous
flow reactors for process development.
The products are developed using principles of quality by design,
incorporating design of experiments (DOE) to develop robust and cost effective
processes.
API R&D has dedicated oncology and polypeptide development labs.
The API Integrated Product Development (IPD) team has rolled out a
programme for adopting principles of Green Chemistry with a vision for developing
processes that are friendly to the environment, like use of enzymatic
transformations, reducing waste generation and recycling of suitable inputs.
Highly experienced analytical research development team houses
instrumentation like NMR, LC-MS-MS, GC-MS, PXRD, single crystal XRD etc.
The capabilities are limitless-from development of a simple achiral molecule to highly
complex multi chiral centres molecule with a distinction of affordability and highest
quality.

PLATFORM TECHNOLOGY

Cipla has made strategic investments in common platform technologies such as

sustained release and combination products, and in key platforms to enhance drug
delivery system capabilities. These technologies enhance the drugs safety and its
efficacy by a targeted therapy approach. In some instances, the convenience of
patients is an important factor.

40
The strategic aim is to formulate differentiated products that overcome the key
challenges of conventional drug delivery systems and add value to current products
.Adopted and developed a range of platform technologies such as:

Nanotechnology
At Cipla, Nanotechnology has been adapted to develop targeted therapies for
diseases like cancer. It involves employing nanosize particles to deliver drugs to
specific types of cells such as cancer cells. The particles are engineered so that they
are attracted to diseased cells which allow direct treatment of those cells. They have
been successful in developing and manufacturing a number of nanotech-based
products such as paclitaxel, fenofibrate and sirolimus, amongst others. The aim is to
prevent unwanted toxicity due to wide distribution, improve patient compliance and
thus provide favourable clinical outcomes.

They also use nanotechnology to address the challenges of undesirable

physiochemical properties of certain drugs which lead to poor pharmacokinetics.
Nano particulate drug delivery systems show a promising approach to obtain
desirable drug-like properties by altering the biopharmaceutics and pharmacokinetics
properties of the molecule.

Microsphere
Microsphere technology is used to develop differentiated formulations for targeted
delivery. They aim to use this technology for a site-specific action, to eliminate
inconvenience of repeated injections and to decrease toxic side-effects.

They have the capability to develop microsphere drugs and up-scale the process for
commercial manufacturing. They have developed, amongst others, microsphere
injection formulations for Leuprolide and Triptorelin.

Liposomal
Liposomal technology is another method used by us to improve the delivery of drugs.
Liposomes offer excellent opportunity to selectively target drugs; which is expected
to optimize the pharma cokinetical parameters, the pharmacological effect and to
reduce the toxicity of the drugs.

41
Using this in-house capability, we have successfully developed liposomal and
Amphotericin B, to name a few.

Hot Melt Extrusion

They have adapted hot melt extrusion capabilities to produce solid molecular
dispersions with considerable advantages over solvent-based processes such as
spray drying and co-precipitation. They use this technology to provide sustained,
modified and targeted drug delivery. They apply this technology for tablets, implants
and topical delivery systems such as topical liposomal formulations and transdermal
patches.

Sustained Release Formulations Technology

They have taken a step forward in the use of novel technology to develop sustained
release tablet formulations. Osmotic-controlled Release Oral Delivery System
(OROS) technology is used to deliver once-daily tablets. This advanced technology
uses osmotic pressure to deliver the drug in several therapeutic areas. It can lead to
improved safety profile, stable drug concentrations, uniform drug effects and reduced
dosing frequency. OROS technology enables the use of an effective starting dose
and eliminates the need for dose titration. This allows symptom control much earlier
than immediate-release tablets. We aim to improve patient convenience and
compliance by applying this technology to various therapies.

Another technology adapted to develop sustained release tablets is the Mutiple-Unit

Pellet System (MUPS) technology. The tablet is made of multiple particulates that
disintegrate into individual pellets, thus providing sustained drug release.

Orally Disintegrating Formulations Technology

They have the capability to develop and manufacture orally disintegrating tablets
which disintegrate rapidly when placed upon the tongue and ensure faster onset of
action. They adapt this technology to several molecules to provide for line extensions
to aid patient convenience and compliance.

42
5. PRODUCTION DEPARTMENT

Production is the functional area responsible for turning inputs into finished outputs
through a series of production processes. The Production Manager is responsible for
making sure that raw materials are provided and made into finished goods
effectively.

The production department in a business organization is that department which

engages in the manufacturing or production of goods for the business organization.
The production department is headed by the production manager. Other workers in
this department include technicians, engineers, designers, machine operators etc.

There are so many functions of the production department. Below are some of the
most common functions of this department:

The production department manufactures goods for the business which are
then sold in order to bring revenue for the business.

The production department is also responsible for the designing of the goods
or products of the business which are sold to other businesses or to the general
public.

Every aspect of production is controlled by the production department. By

controlling production, the department efficiently uses things such as labor,
machines and materials judiciously in order to prevent any wastage.

The department improves on the products of the business by bringing

changes and innovations.

The production department makes sure that it produces goods or products at

very low costs in order to maximize profit.

43
 The production department works in collaboration with the purchasing
department of the company in order to make sure that materials needed for
production are always available.

The department also makes sure that the machines and equipments used in
production are serviced and properly maintained all the time.

Storage
Planning Stores Purchase Approved
departmen suppliers Stores
t
conditions

Cipla other
unit

Other cipla
units

Export

44
 Stores productio Dispenci Stores
ng
n
QC

Local
sales

Supplie 4Bnu1b
r 67V
Under

The production department in a business organization is that department which

engages in the manufacturing or production of goods for the business organization.
The production department is headed by the production manager. Other workers in
this department include technicians, engineers, designers, machine operators etc .

The production and planning department in Cipla is set standards and targets for
each section of the production process. The quantity and quality of products coming
off a production line will be closely monitored. In businesses focusing on lean
production, quality will be monitored by all employees at every stage of production,
rather than at the end as is the case for businesses using a quality control approach.

The purchasing department in cipla is responsible for providing the materials,

components and equipment required to keep the production process running
smoothly. A vital aspect of this role is ensuring stocks arrive on time and to the right
quality.

The stores department will be responsible for stocking all the necessary tools,
spares, raw materials and equipment required to service the manufacturing process.
Where sourcing is unreliable, buffer stocks will need to be kept and the use of
computerised stock control systems helps keep stocks at a minimal but necessary
level for production to continue unhindered.

In production department then arrange the workers and suppliers for the production.
After that they send the production samples to QC department for checking the

45
quality of the products. Then after that they divide and stored the produced items for
exports and local sales.

OUALITY CONTROL DEPARTMENT

Each person involved in making a product is responsible for making it a quality
product. Quality departments, The Quality Departments exist as an
audit function within the manufacturing and packaging areas.

Quality control emphasizes testing of products to uncover defects and reporting to

management who make the decision to allow or deny product release, where as
quality assurance attempts to improve and stabilize production (and associated
processes) to avoid, or at least minimize, issues which led to the defect(s) in the first
place. For contract work, particularly work awarded by government agencies, quality
control issues are among the top reasons for not renewing a contract.

The quality manual gives the quality guidance to different departments and
functions. Therefore, everyone in the organization needs to be aware of his or her
responsibilities mentioned in the quality manual.

The pharmaceutical industry, as a vital segment of the health care system conducts
research, manufacturing and marketing of pharmaceuticals and biological products
and medicinal devices used for the diagnosis and treatment of diseases. The poor
qualities of medicines are not only a health hazard, but also a waste of money for
both government and individual consumers. Therefore, the maintenance of quality
with continuous improvement in facilities is very important in pharmaceutical
industries. The pursuit of quality being approached through the concept of total

46
quality management (TQM) system which is aimed at prevention of defects rather
than detection of defects

The concept of total quality control refers to the process to produce a perfect
product by a series of measures requiring an organized effort by the entire company
to prevent or eliminate errors at every stage in production.

The overall system of activities whose purpose is to control the quality of a product
or service so that it meets the needs of users. The aim is to provide quality that is
satisfactory, adequate, dependable and economic. It represents the mechanism
established to control errors.

Receiving the complaints/ verbal

Forwarding to heads of QA department

Investigation of the complaints

Report( product, complaint, sample, action

taken etc. Details)

Assigning a specific PCR number EX:

PCR/001/11.

47
 Recall if any

Maintenance of register of complaints

Procedures in QC

Materials

Receipt

Verification

Sampling

Under test

QC testing
48

For Return to
Approved Rejected
manufacturi suppliers
In cipla the QC department check and verifies the quality of the products. In this they
took the samples of the products and test the various QC test and approved the
quality of the products .In cipla in QC department uses various software for the
testing of the products. Lambda25 and Perkin Elmer are the softwares that they use
in the QC department. After the testing in the QC department they send the
approved products for manufacturing and the rejected items are return to the
suppliers.

7. QUALITY ASSURANCE DEPARTMENT

Quality Assurance is a broad practice used for assuring the quality of products or
services. There are many differences between quality control and quality
assurance.

Quality assurance function of an organization uses a number of tools for enhancing

the quality practices. These tools vary from simple techniques to sophisticated
software systems.

It is the way of preventing mistakes or defects in manufactured products and

avoiding problems when delivering solutions or services to customers

49
The quality assurance professionals also should go through formal industrial
trainings and get them certified. This is especially applicable for quality assurance
functions in software development houses.

Since quality is a relative term, there is plenty of opportunity to enhance the quality
of products and services.

The quality assurance teams of organizations constantly work to enhance the

existing quality of products and services by optimizing the existing production
processes and introducing new processes.

The assurance of quality of the product depends on more than just proper sampling
and adequate testing of various components and finished dosage forms (products).
Prime responsibility of maintaining the product quality during production rests with
the manufacturing department. Quality assurance personnel must establish control
or check points to monitor the quality of the product as it is processed and up to
completion of manufacturing. This begins with raw materials and component testing
and includes in-process packaging, labelling and finished product testing as well as
batch auditing and stability monitoring.

50
CHAPTER 4

51
 SWOT ANALYSIS
SWOT ANALYSIS

STRENGTH
Developed good positive image by providing support to cancer patients
by issuing drugs at low cost .

Cipla Ltd., one of India's largest generic drug manufacturers, said it is cutting prices
on its cancer medicines by up to 75%, a move likely to further complicate efforts by
big Western pharmaceutical companies seeking to develop their businesses in India.

In Cipla they provide medicines for the cancer patients at lower cost as compare to
the other pharmaceutical industries. For this they use low cost technologies and
materials and provide the medicines at low costs.

Cipla cut the price of its generic version of Nexavar to 6,840 rupees ($128) for a
month's supply from 28,000 rupees ($523). Bayer's patented medicine costs 280,000
rupees ($5,234) for a month. Cipla also slashed the cost of its copies of
AstraZeneca PLC's lung-cancer drug Iressa by almost 60% and brain-cancer drug
temozolamide by 75%. Bayer declined to comment on Cipla's move, while
AstraZeneca couldn't be immediately reached for comment.

Y. K. Hamied, Cipla's chairman and managing director, cast the move as an attempt
to bring cheap cancer medicines to the world, just as the company became a
champion of HIV patients in Africa a decade ago by using its cheaper manufacturing
base to sell AIDS drugs at a deep discount.

3rd position in Indian market

Cipla is the third positionin the Indian market in the ORG-IMS rankings for the month
of November with a market share of 5.42 per cent and sales of Rs 146.32 crore,
edging out Ranbaxy which stood at second position with 5.09 per cent market share

52
and Rs 137.49 crore sales. Sun Pharma and Abott are the first and second positions
in the Indian market.

A foremost player in anti-infective and anti-asthmatic formulations

Forty years ago, Cipla started its fight against heart disease with innovative and high-
class drugs. They introduced Propranolol, the first beta blocker in India way back in
1972. This ushered in a new age of affordable beta blockers. Over the years, they
have developed several products that help treat various diseases like MI, angina,
heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, and obesity.
Apart from innovation in cardiology, They also provide valuable services to the
medical fraternity, in the form of the latest medical updates, CMEs and workshops.
Not to mention many international symposia and webcasts with the worlds leading
minds in cardiology, and conferences conducted in collaboration with international
scientific bodies.

Skilled workforce

Cipla employees handpicked professionals not just for their knowledge and
experience but for their zeal to make a difference to the world of healthcare.

The company believes that their biggest assets are the employees, who lead us to
prosperity and growth in the future. Driven by the vision, None shall be denied,
Ciplas focus has always been on making affordable, world-class medicines with a
reputation for uncompromising quality standards across the world.

Has a strong employee force of over 20000

Cipla having more than 20000 employees .So they consider the workers are the
strength of the company. They helps for the growth and development of the
company. The company believes that our biggest assets are the employees, who
lead us to prosperity and growth in the future. Driven by the vision, None shall be
denied, Ciplas focus has always been on making affordable, world-class medicines
with a reputation for uncompromising quality standards across the world.

High profitability and revenue

Cipla having high profitability and revenue. Cipla have revenue 108.83 billion.

53
 The high profitability and revenue are consider as the strength of the Cipla.

Experienced business unit

Cipla started their business in 1935 onwards . Apart from the various national and
international milestones, the story of Ciplas growth and expansion, its ups and
downs, successes and challenges is also one that deserves to be chronicled.
According to Dr Y K Hamied, Cipla was ranked 56 in the 1960s

WEEKNESS.

High dependence of few key products

Ciplas main product is inhaler and other cardiovascular diseases products. So they
mainly focused on these products. Because of that they less invented other new
products.

Work load is high and employee turnover is also high

CIpla having employee turnover is high because of high work load. Heavy
workloads can negatively affect the psychological well-being of employees. High
turnover may be harmful to a company's productivity if skilled workers are often
leaving and the worker population contains a high percentage of novices. In Cipla
there having no job rotation, so this may also causes for the employee turn over.

54
 OPPORTUNITIES

It can venture into many disease medication

Cipla introduced medicines for many diseases. Ciplas commitment to womens

health began in 1979, with the launch of Clominphene citrate for infertility in women.
Cipla MDIs are designed to deliver accurate and consistent dosing by using the most
sophisticated metered dose valves, canisters and actuators. Forty years ago, Cipla
started its fight against heart disease with innovative and high-class drugs. They
introduced Propranolol, the first beta blocker in India way back in 1972. They also
introduced medicines for HIV/ AIDS, oncology,malariya,urology etc..

New therapy approaches

Cipla introduced various new theraphies like oncology, urology etc.Cipla are present
in 9 key pediatric therapeutic segments:

Anti-bacterials
Gastro-intestinals
Anti-asthmatics
Nutritional supplements
Allergic Rhinitis therapy
Anti-pyretic medicines
Surfactant therapy for premature babies
Chelation therapy
Growing demand

The demand of the medicines from Cipla is increasing and Cipla become the third
largest pharmaceutical company in the Indian market .By the use of the fast foods
and the way of living people having many diseases and automatically the demand of

55
the medicines also increases

Growing income and growing attention to health

Today the living condition of the people is entirely different than the early days.
The income of the people is increases and also their attention to the health also
increases. So this become the opportunity of the pharmaceutical companies.

THREATS

High cost of discovery new products and few discoveries.

The development of a new drug requires a major investment of capital, human

resources, and technological expertise. It also requires strict adherence to
regulations on testing and manufacturing standards before a new drug can be used
in the general population. The items for manufacturing for the medicine is too costly
so as the result the few discoveries.

Prices of medicines rises

The trends are clear: patients and institutions across the nation are concerned
about skyrocketing drug prices. This post offers some information about drug
pricing, explores the notion of market intervention, and proposes a series of
responses to high pharmaceutical costs. So due to the increase in price of the
medicines the poor people face difficult to buy the medicines.

High competitions

The pharmaceutical sector is, perhaps uniquely, an industry in which the normal
processes of competition do not work in a textbook manner. On the demand side,
apart from standard over-the counter medicines, we do not have individual
consumers exercising their freedom to choose between competing products, based
on their features and relative prices. Although the exact chemical composition of
medicines is mandatorily printed on the packaging, most consumers are not qualified
to understand the pharmacological properties of these ingredients.

In India having many pharmaceutical industries and having high competition in the
market. This become the threat of the pharmaceutical industries.

The government companies provide free medicines

56
India is proposing an ambitious plan to substantially raise spending on providing free
drugs for Indias 1.2 billion population.

India has put in place a $5.4 billion policy to provide free medicine to its people, a
decision that could change the lives of hundreds of millions, but a ban on branded
drugs stands to cut Big Pharma out of the windfall. The sector is a major source for
various medicines, drugs and other related pharmaceutical formulations. The main
aim of these public sector companies is to manufacture quality products and to
distribute to all at affordable prices. There are mainly five government owned
pharmaceutical companies in the country. Indian Drugs and Pharmaceuticals Ltd.
(IDPL), Hindustan Antibiotics Limited (HAL), Bengal Chemicals and Pharmaceuticals
Limited (BCPL) etc. Are the major government pharmaceutical companies in India.

The government plans to roll out a nationwidefree medicine scheme by November,

which will offer quality essential drugs to all the patients in state-run hospitals and
treatment centres, a senior health ministry official said.

The main aim of the companies is to the welfare of the public. So they provide the
medicines freely to the people. It become one of the threat of the growth of the
private pharmaceutical companies in India.

57
 CHAPTER 5
FINDINGS AND CONCLUSION

58
FINDINGS

The important findings from this organizational study are as the followings:

The Cipla Limited has an excellent organizational structure.

Cipla employees handpicked professionals not just for their knowledge and
experience but for their zeal to make a difference to the world of healthcare.

The Cipla Ltd focuses on the service quality of its employees who are working
up to the required standards.

Cipla is focused towards developing new products, improving existing

products as well as drug delivery systems and expanding product applications.

Cipla is the 3rd largest pharmaceutical industry in India.

Cipla launched Cipla New Ventures (CNV), as its impact investment arm, to
nurture and build innovation-led business streams for Cipla, distinct from the
mainstream business of today and tomorrow.

Being a good corporate citizen is an integral part of Ciplas core value. Over
the last three decades, the Company has carried out various CSR activities
directly and through its trusts. Making quality medicines at affordable prices
has always been Ciplas focus.

In a humanitarian effort to support cancer patients, the Company made a

59
 breakthrough in reducing the prices of cancer drugs, thus making world-class
medicines accessible to patients in India.

CONCLUSION

The organization study provided useful insight about the company and its functioning.
It was a great experience in doing of my life to got trained in Cipla with supportive
staffs and trainees. I got lot of fruitful inputs on how the organization functions and
how the follow ups are done. I got lot of valuable information and knowledge from the
company and expose ourselves to corporate politics, ethics, culture, practices,
procedures, facts about the work culture and policies of the company.

The activities of all departments are functioning at the impressive standards for
achieving the Organizational objectives. Flexibility, work culture and the management
approach towards the employees are the main factor which drives satisfaction to
each of the employees at Cipla Limited. A real life experience which was enough for
figuring out of the structure and functioning of the Human Resources department.

60
 BIBLIOGRAPHY

REFERENCES

Annual report of Cipla of the year: 2014-2015.

WEBSITES AND URL

www.cipla.com
https:// sambanth.cipla.com
www.mediindia.net.com
https://www.pharmacy.org
www.impharmation.in

61
.

62